Analysts at BidaskScore Give Sonoma Pharmaceuticals (NASDAQ:SNOA) an Upgrade

Sonoma Pharmaceuticals (NASDAQ:SNOA) Stock Upgrade

In a research report sent to investors and clients on 14 March, BidaskScore raised their rating for shares of Sonoma Pharmaceuticals (NASDAQ:SNOA) to a “Sell”.

The stock increased 1.92% or $0.02 during the last trading session, reaching $1.06. About 66,720 shares traded. Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) has declined 75.07% since March 15, 2018 and is downtrending. It has underperformed by 79.44% the S&P500.

Analysts await Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) to report earnings on June, 12. They expect $-0.20 earnings per share, up 78.49 % or $0.73 from last year’s $-0.93 per share. After $-0.26 actual earnings per share reported by Sonoma Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -23.08 % EPS growth.

Sonoma Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and markets solutions for the treatment of dermatological conditions and advanced tissue care in the United States, Latin America, Europe, and internationally. The company has market cap of $12.69 million. The firm offers Microcyn line of products that are based on electrically charged oxychlorine small molecules designed to target a range of pathogens, such as viruses, fungi, and spores, as well as bacteria, including antibiotic-resistant strains. It currently has negative earnings. The Company’s products also include Celacyn, a prescription hypochlorous acid based scar management gel; Ceramax Skin Barrier Cream to manage dry itchy skin, minor skin irritations, rashes, and inflammation; Mondoxyne, a prescription oral tetracycline antibiotic for the treatment of various bacterial infections; Alevicyn, a prescription hypochlorous acid based atopic dermatitis product line to reduce itch and pain associated with various dermatoses; and SebuDerm, a prescription topical gel for the management of burning, itching, and scaling in seborrhea and seborrheic dermatitis.

More notable recent Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) news were published by: Seekingalpha.com which released: “Akers Biosciences leads Healthcare gainers; Sonoma Pharmaceuticals leads the losers – Seeking Alpha” on November 19, 2018, also Nasdaq.com with their article: “Earnings Estimates Going Higher – Nasdaq” published on February 02, 2018, Seekingalpha.com published: “Sonoma Pharma readies equity offering; shares down 2% – Seeking Alpha” on November 07, 2018. More interesting news about Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) were released by: Seekingalpha.com and their article: “FDA approved Sonoma’s antimicrobial claim for Alevicyn gel products for management of atopic dermatitis – Seeking Alpha” published on December 05, 2017 as well as Globenewswire.com‘s news article titled: “Sonoma Pharmaceuticals Announces Results from SebuDermâ„¢ Gel Study in Treatment of Seborrheic Dermatitis – GlobeNewswire” with publication date: March 16, 2017.

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.